Bbva Compass Bancshares Inc. raised its holdings in Anika Therapeutics Inc (NASDAQ:ANIK) by 32.7% during the first quarter, HoldingsChannel reports. The firm owned 12,737 shares of the biotechnology company’s stock after acquiring an additional 3,137 shares during the quarter. Bbva Compass Bancshares Inc.’s holdings in Anika Therapeutics were worth $385,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of ANIK. Financial Gravity Companies Inc. acquired a new stake in shares of Anika Therapeutics in the 4th quarter valued at $52,000. Quantamental Technologies LLC acquired a new stake in shares of Anika Therapeutics in the 1st quarter valued at $69,000. Massmutual Trust Co. FSB ADV acquired a new stake in shares of Anika Therapeutics in the 4th quarter valued at $76,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Anika Therapeutics by 356.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,891 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 2,257 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan acquired a new stake in shares of Anika Therapeutics in the 4th quarter valued at $140,000. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Joseph G. Darling purchased 1,000 shares of the company’s stock in a transaction dated Thursday, February 28th. The stock was bought at an average cost of $33.20 per share, for a total transaction of $33,200.00. Following the purchase, the chief executive officer now owns 22,436 shares of the company’s stock, valued at $744,875.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Raymond J. Land sold 4,000 shares of the stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $33.06, for a total value of $132,240.00. Following the completion of the transaction, the director now owns 18,992 shares of the company’s stock, valued at $627,875.52. The disclosure for this sale can be found here. 3.67% of the stock is currently owned by corporate insiders.

ANIK has been the topic of a number of research analyst reports. Sidoti set a $35.00 target price on Anika Therapeutics and gave the company a “hold” rating in a report on Tuesday, March 5th. Zacks Investment Research downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 20th. Barrington Research reduced their target price on Anika Therapeutics to $44.00 and set an “outperform” rating on the stock in a report on Friday, February 22nd. First Analysis downgraded Anika Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $41.00 to $37.00 in a report on Friday, February 22nd. Finally, BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, February 20th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $40.00.

Shares of ANIK opened at $38.22 on Thursday. Anika Therapeutics Inc has a 52 week low of $28.54 and a 52 week high of $46.43. The firm has a market capitalization of $542.99 million, a PE ratio of 20.77, a PEG ratio of 2.99 and a beta of 1.41. The company has a debt-to-equity ratio of 0.08, a current ratio of 18.07 and a quick ratio of 16.12.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. Anika Therapeutics had a return on equity of 11.57% and a net margin of 27.44%. The company had revenue of $24.72 million during the quarter, compared to analysts’ expectations of $22.06 million. During the same period in the prior year, the company earned ($0.46) EPS. Anika Therapeutics’s revenue was up 16.3% compared to the same quarter last year. As a group, analysts expect that Anika Therapeutics Inc will post 1.28 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2019/05/16/bbva-compass-bancshares-inc-has-385000-position-in-anika-therapeutics-inc-anik.html.

Anika Therapeutics Profile

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Featured Article: What is a Market Correction?

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.